BioCentury | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

...in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Sandi Wong, Staff Writer ASTX727 EBV-CTL, tab-cel, tabelecleucel (ata 129, ata129) LJPC-401 Ninlaro...
BioCentury | Apr 6, 2018
Finance

Fundamentally driven

...year -- FDA cleared the company to begin two Phase III trials of tabelecleucel (formerly ATA129...
...Brand), XL184 (Compound #), cabozantinib (Generic), Cometriq (Other), Cabometyx (Other) Darzalex, daratumumab (JNJ-54767414, humax-cd38) EBV-CTL, tabelecleucel (ata 129, ata129) Feraccru...
BioCentury | Mar 9, 2018
Financial News

Atara raises $150M in follow-on

...the offering after market hours. Atara is conducting two Phase III trials of tabelecleucel (formerly ATA129...
...that offering (see BioCentury, Jan. 5 ). Atara Biotherapeutics Inc. (NASDAQ:ATRA), South San Francisco, Calif. Paul Bonanos ATA129 tabelecleucel Atara...
BioCentury | Mar 1, 2018
Financial News

Atara raises another $150M in latest follow-on

...$1.33 to $37.20 on Thursday. Atara is conducting two Phase III trials of tabelecleucel (formerly ATA129...
BioCentury | Jan 26, 2018
Clinical News

Atara reports expanded access protocol data of tabelecleucel

...5 ). Atara Biotherapeutics Inc. (NASDAQ:ATRA), South San Francisco, Calif. Product: Tabelecleucel (formerly EBV-CTL, ATA 129, ATA129...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...and EAGLE data 1H18 Atara Biotherapeutics Inc. (NASDAQ:ATRA) / Memorial Sloan Kettering Cancer Center EBV-CTL (ATA129...
BioCentury | Jan 5, 2018
Clinical News

Atara begins Phase III testing of tabelecleucel to treat EBV-PTLD

...in 1H19. Atara Biotherapeutics Inc. (NASDAQ:ATRA), South San Francisco, Calif. Product: Tabelecleucel (formerly EBV-CTL, ATA 129, ATA129...
BioCentury | Jan 5, 2018
Financial News

Atara prices $127.8M follow-on

...cleared it to begin the open-label Phase III MATCH and ALLELE trials of tabelecleucel (formerly ATA129...
BioCentury | Jan 4, 2018
Financial News

Atara prices $127.8M follow-on

...cleared it to begin the open-label Phase III MATCH and ALLELE trials of tabelecleucel (formerly ATA129...
...and PRIority MEdicines (PRIME) designation from EMA. Atara was off $1.25 to $18.00 on Thursday. Jennie Walters ATA129 EBV-CTL Rituxan rituximab tabelecleucel Atara...
BioCentury | Dec 29, 2017
Clinical News

Atara gains on Phase III plans for cell therapy

...Friday after FDA cleared the company to begin two Phase III trials of tabelecleucel (formerly ATA129...
...it plans to submit a conditional marketing authorization application in the EU in 1H19. Jaime De Leon ATA129 Rituxan rituximab Atara...
Items per page:
1 - 10 of 25